Cyclerion's 400% Stock Surge Follows Bold Korsana Merger and Alzheimer's Drug Bet

Shares of Cyclerion Therapeutics surged by over 400% on Wednesday after the company announced a merger with Korsana Biosciences. The deal, structured as a reverse takeover, will see the combined entity rebrand as Korsana and trade on the Nasdaq under the ticker 'KRSA'. The merger follows Cyclerion's strategic review, which concluded with a decision to prioritise Korsana's pipeline over its own legacy programs. Under the terms of the all-stock agreement, existing Cyclerion shareholders will retain just 1.5% of the new company, while Korsana's investors will hold 98.5%. This shift effectively positions the combined entity as a bet on Korsana's management and drug development efforts rather than Cyclerion's past work.

Cyclerion's most recent financial report showed $2.07 million in revenue and a net loss of $3.53 million. The company's stock price spike reflects investor confidence in Korsana's lead program, **KRSA-028**, a Phase 1 shuttled monoclonal antibody targeting Alzheimer's disease. However, human efficacy data for the drug is not expected until late 2027. The merger coincides with a $380 million private investment round, led by Fairmount and Venrock Healthcare Capital Partners. This funding is projected to support operations through 2029, giving Korsana a multi-year runway to advance its clinical programs. Jonathan Violin, Korsana's current CEO, will lead the combined company, with Tomas Kiselak of Fairmount serving as chairman.

The newly formed Korsana Biosciences will focus on developing KRSA-028, its experimental Alzheimer's treatment. With fresh capital and a streamlined leadership team, the company now operates under a new Nasdaq listing. The merger marks a clear shift away from Cyclerion's previous projects toward Korsana's pipeline.